EUCTR2016-001794-32-FR进行中（未招募）1 期
A Phase II, Multicenter, Non Randomized, Open Label Study of Nivolumab In Recurrent and/or Metastatic Salivary Gland Carcinoma of the Head and Neck. - NISCAH
ICANCER0 个研究点目标入组 92 人开始时间: 2016年11月30日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 92
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1) Adult men and women = 18 years
- •2) Histologically confirmed carcinoma of the salivary glands, recurrent or metastatic (adenoid cystic carcinoma or non-adenoid cystic carcinoma) not eligible to local treatment
- •3) Pre-treatment tumor tissue available for central review and biomarkers analysis.
- •4) At least one measurable lesion = 10 mm (outside any previous irradiated field) according to RECIST 1.1 criteria with MRI or CT-scan
- •5) Patients with confirmed disease progression at study entry. The ”baseline” radiological evaluation (either MRI or CT scan) should demonstrate disease progression by RECIST 1.1 when compared to a prior disease assessment done within a 6 months period prior to screening.
- •6) Previous anti-cancer therapies must be discontinued at least 4 weeks prior to administration of study drug. Concomitant, palliative (limited-field) radiation therapy is permitted during the study, if all of the following criteria are met:
- •- Repeated imaging demonstrates no new sites of bone metastases.
- •- The lesion being considered for palliative radiation is not a target lesion.
- •7) Performance status ECOG < 2
- •8) Screening laboratory values must meet the following criteria and should be obtained within 7 days prior to starting study drug: WBC = 2000/mm3, Neutrophils = 1500/mm3, Platelets = 100 000 /mm3, Hemoglobin > 9.0 g/dL, Serum creatinine = 1.5 x ULN or creatinine clearance (CrCl) = 40 mL/min (using the Cockcroft-Gault formula), AST/ALT/PAL = 3 x ULN or = 5 x ULN when liver metastases, Total Bilirubin = 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
- •9) Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug
- •10) Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of nivolumab
- •11) Women who are breastfeeding should discontinue nursing prior to the first dose of study drug and until 6 months after the last dose.
- •12) Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year. Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product. Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile as well as azoospermic men do not require contraception).
- •13) Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses.
- •14) Patients with social insurance coverage.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 46
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 46
排除标准
- •1) Stable disease
- •2) Symptomatic / active brain metastases.
- •3) Immunosuppressive doses of systemic corticosteroids (> 10 mg/day prednisone equivalents) within 2 weeks prior to study drug administration. A 2 weeks wash-out minimum is required before starting study drug.
- •4) Patients with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.
- •5) Patients with any active or suspected autoimmune disease or an history of known autoimmune disease (Patients with vitiligo, type I diabetes mellitus, residual hypothyroidism due to an autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are however eligible for this trial).
- •6) Patients having received prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody (or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
- •7) History of organ transplantation requiring long-term immunosuppressive medications
- •8) Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
- •9) Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection
- •10) Known history or active tuberculosis
- •11) Any other malignancy (except for appropriately treated superficial basal cell skin cancer and surgically cured in situ cancer) unless free of disease for at least three years
- •12) History of allergy to study drug components
- •13) Any toxicity (other than alopecia) attributed to prior anti-cancer therapy not resolved to grade 1 (NCI CTCAE version 4) at baseline level before administration of study drug.
- •14) Known or underlying medical condition (e.g., a condition associated with diarrhea or acute diverticulitis) that, in the investigator’s opinion, would make the administration of study drug hazardous to the patient or obscure the interpretation of toxicity determination or adverse events.
- •15) History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance of oral drug intake (if applicable).
- •16) Unwillingness to give written informed consent, unwillingness to participate, or inability to comply with the protocol for the duration of the study.
- •17) Individuals deprived of liberty or placed under the authority of a tutor.
- •18) Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to enrolment and during the treatment period.
研究者
相似试验
进行中（未招募）
1 期
A Phase II multi-center, non-randomized, open-label study of TKI258 in patients with either FGFR3 mutated or FGFR3 wild type advanced urothelial carcinoma - N/APatients with either FGFR3 mutated or FGFR3 wild type advanced urothelial carcinomaMedDRA version: 12.0Level: LLTClassification code 10064467Term: Urothelial carcinomaEUCTR2008-005870-11-NLovartis Pharma Services AG
进行中（未招募）
1 期
A Phase II multi-center, non-randomized, open-label study of TKI258 in patients with either FGFR3 mutated or FGFR3 wild type advanced urothelial carcinomaPatients with either FGFR3 mutated or FGFR3 wild type advanced urothelial carcinomaMedDRA version: 14.0 Level: LLT Classification code 10064467 Term: Urothelial carcinoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-005870-11-GBovartis Pharma Services AG
进行中（未招募）
不适用
A Phase II multi-center, non-randomized, open-label study of TKI258 in patients with either FGFR3 mutated or FGFR3 wild type advanced urothelial carcinoma - N/AEUCTR2008-005870-11-ATovartis Pharma Services AG99
进行中（未招募）
不适用
A Phase II multi-center, non-randomized, open-label study of TKI258 in patients with either FGFR3 mutated or FGFR3 wild type advanced urothelial carcinoma - N/AMedDRA version: 13.1Level: LLTClassification code 10064467Term: Urothelial carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Patients with either FGFR3 mutated or FGFR3 wild type advanced urothelial carcinomaEUCTR2008-005870-11-DEovartis Pharma Services AG80
撤回
2 期
A Phase II multi-center, non-randomized, open-label study of TKI258 in patients with either FGFR3 mutated or FGFR3 wild type advanced urothelial carcinoma.advanced bladdercarcinoma10038364NL-OMON36264ovartis4